Who Paid My Doc
Farlyn Charlot-Wadley
Podiatrist, Foot Surgery New Haven, CT Doctor of Podiatric Medicine
NPI 1538339080 CMS profile 69327
508 Blake St, New Haven, CT 06515
General payments
$4,377
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Farlyn Charlot-Wadley of New Haven, CT is reported in the CMS Open Payments database as having received $4,377 across 45 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 84th percentile of Podiatrist, Foot Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $534 | 7 | |
| 2024 | General | $169 | 2 | |
| 2023 | General | $436 | 4 | |
| 2022 | General | $343 | 5 | |
| 2021 | General | $1,326 | 5 | |
| 2020 | General | $335 | 4 | |
| 2019 | General | $1,235 | 18 |
Beside peers
- Farlyn Charlot-Wadley
- Podiatrist, Foot Surgery median
- Middle half of Podiatrist, Foot Surgery
- National median
In program year 2025, general payments to Farlyn Charlot-Wadley were reported at $534. Among 732 Podiatrist, Foot Surgery profiles paid that year, the median was $180 and the middle half received between $70 and $569.
Show as a table
| Year | Farlyn Charlot-Wadley | Podiatrist, Foot Surgery median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $1,235 | $167 | $67–$484 | $163 |
| 2020 | $335 | $114 | $40–$323 | $114 |
| 2021 | $1,326 | $171 | $57–$502 | $132 |
| 2022 | $343 | $196 | $66–$556 | $149 |
| 2023 | $436 | $187 | $78–$466 | $160 |
| 2024 | $169 | $190 | $78–$557 | $164 |
| 2025 | $534 | $180 | $70–$569 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 11 drugsPart D claims
338
Drug cost
$8,323
Branded share of claims
22.2%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Ciclopirox | Generic | 77 | $3,038 | |
| Ciclopirox Ciclopirox Olamine | Brand | 61 | $1,697 | |
| Ammonium Lactate | Generic | 38 | $738 | |
| Pregabalin | Generic | 21 | $661 | |
| Neomycin-Polymyxin-Hydrocort Neomycin/Polymyxin B/Hydrocort | Brand | 14 | $602 | |
| Diclofenac Sodium | Generic | 18 | $444 | |
| Fluconazole | Generic | 20 | $314 | |
| Clotrimazole | Generic | 24 | $298 | |
| Mupirocin | Generic | 25 | $199 | |
| Ketoconazole | Generic | 20 | $193 |
The 10 drugs with the highest cost, of 11 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 55 billing codesPaid by Medicare
$38,052
Medicare patients
199
Services billed
622
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Diabetes | 50% | |
| Arthritis | 49% | |
| Ischemic heart disease | 34% | |
| Chronic kidney disease | 28% | |
| Heart failure | 20% | |
| Cancer | 19% | |
| Depression | 18% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 | Office | 12 | 15 | $11 |
| Injection, dexamethasone sodium phosphate, 1 mg J1100 | Office | 12 | 62 | $5 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
45 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Podiatrist, Foot Surgery in Connecticut
Raffaella Pascarella
Podiatrist, Foot Surgery · Bloomfield, CT
Manal Anz
Podiatrist, Foot Surgery · Shelton, CT
Leo Veleas
Podiatrist, Foot Surgery · Southington, CT
Anthony Babigian
Podiatrist, Foot Surgery · Norwalk, CT
Catherine Jacobs
Podiatrist, Foot Surgery · Hartford, CT
Benedict Valentine
Podiatrist, Foot Surgery · Marlborough, CT
Related records
Podiatrist, Foot Surgery in Connecticut
Practitioners in the same specialty and state, ranked by reported value.
All Podiatrist, Foot Surgery
Everyone recorded under this specialty, nationwide.
Doctors in Connecticut
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.